Terms: = Uterine cancer AND BTG1, P62324, 694, ENSG00000133639 AND Treatment
18 results:
1. Race, Prevalence of POLE and POLD1 Alterations, and Survival Among Patients With Endometrial cancer.
Zheng S; Donnelly ED; Strauss JB
JAMA Netw Open; 2024 Jan; 7(1):e2351906. PubMed ID: 38231514
[TBL] [Abstract] [Full Text] [Related]
2. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract] [Full Text] [Related]
3. Prediction of postoperative reintervention risk for uterine fibroids using clinical-imaging features and T2WI radiomics before high-intensity focused ultrasound ablation.
Qin S; Lin Z; Liu N; Zheng Y; Jia Q; Huang X
Int J Hyperthermia; 2023; 40(1):2226847. PubMed ID: 37394476
[TBL] [Abstract] [Full Text] [Related]
4. Unsuspected placenta accreta spectrum at vaginal delivery: assessment of incidence, characteristics, and maternal morbidity.
Rau AR; Youssefzadeh AC; Matsuzaki S; Mandelbaum RS; Ouzounian JG; Matsuo K
Am J Obstet Gynecol MFM; 2023 May; 5(5):100805. PubMed ID: 36774226
[TBL] [Abstract] [Full Text] [Related]
5. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.
Jamieson A; Huvila J; Leung S; Chiu D; Thompson EF; Lum A; Kinloch M; Helpman L; Salvador S; Vicus D; Kean S; Samouelian V; Grondin K; Irving J; Offman S; Parra-Herran C; Lau S; Scott S; Plante M; McConechy MK; Huntsman DG; Talhouk A; Kommoss S; Gilks CB; McAlpine JN
Gynecol Oncol; 2023 Mar; 170():282-289. PubMed ID: 36753816
[TBL] [Abstract] [Full Text] [Related]
6. Higher clearance rates of multiple HPV infections may explain their lower risk of HSIL: A retrospective study in Wenzhou, China.
Ni X; Hu J; Huang Y; Tao J; Zhu H
J Med Virol; 2023 Feb; 95(2):e28526. PubMed ID: 36698241
[TBL] [Abstract] [Full Text] [Related]
7. Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer.
Yavas G; Yavas C; Sen E; Oner I; Celik C; Ata O
Int J Gynecol Cancer; 2019 Jan; 29(1):42-47. PubMed ID: 30640682
[TBL] [Abstract] [Full Text] [Related]
8. Correlations of MicroRNA-21 Gene Polymorphisms With Chemosensitivity and Prognosis of Cervical cancer.
Zhang J; Li YH; Liu HL; Zhang Y; Zhang QS; Li SZ
Am J Med Sci; 2018 Dec; 356(6):544-551. PubMed ID: 30447706
[TBL] [Abstract] [Full Text] [Related]
9. Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).
Olorunfemi G; Ndlovu N; Masukume G; Chikandiwa A; Pisa PT; Singh E
Int J Cancer; 2018 Nov; 143(9):2238-2249. PubMed ID: 29786136
[TBL] [Abstract] [Full Text] [Related]
10. Association of the U.S. Food and Drug Administration Morcellation Warning With Rates of Minimally Invasive Hysterectomy and Myomectomy.
Barron KI; Richard T; Robinson PS; Lamvu G
Obstet Gynecol; 2015 Dec; 126(6):1174-1180. PubMed ID: 26595561
[TBL] [Abstract] [Full Text] [Related]
11. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
[TBL] [Abstract] [Full Text] [Related]
12. The prognostic significance of pretreatment [18F]FDG-PET/CT imaging in patients with uterine cervical cancer: preliminary results.
Cho SH; Lim JY; Kim SN; Hong S; Chung HW; So Y; Kim WY; Lee SJ
Eur J Gynaecol Oncol; 2015; 36(1):30-5. PubMed ID: 25872331
[TBL] [Abstract] [Full Text] [Related]
13. Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).
Kato T; Takashima A; Kasamatsu T; Nakamura K; Mizusawa J; Nakanishi T; Takeshima N; Kamiura S; Onda T; Sumi T; Takano M; Nakai H; Saito T; Fujiwara K; Yokoyama M; Itamochi H; Takehara K; Yokota H; Mizunoe T; Takeda S; Sonoda K; Shiozawa T; Kawabata T; Honma S; Fukuda H; Yaegashi N; Yoshikawa H; Konishi I; Kamura T;
Gynecol Oncol; 2015 Apr; 137(1):34-9. PubMed ID: 25662625
[TBL] [Abstract] [Full Text] [Related]
14. Direct costs of cervical cancer management in Morocco.
Berraho M; Najdi A; Mathoulin-Pelissier S; Salamon R; Nejjari C
Asian Pac J Cancer Prev; 2012; 13(7):3159-63. PubMed ID: 22994727
[TBL] [Abstract] [Full Text] [Related]
15. The value of diffusion-weighted magnetic resonance imaging in assessing the response of locally advanced cervical cancer to neoadjuvant chemotherapy.
Fu C; Bian D; Liu F; Feng X; Du W; Wang X
Int J Gynecol Cancer; 2012 Jul; 22(6):1037-43. PubMed ID: 22683941
[TBL] [Abstract] [Full Text] [Related]
16. Impact of payer status on treatment of cervical cancer at a tertiary referral center.
Levinson KL; Bristow RE; Donohue PK; Kanarek NF; Trimble CL
Gynecol Oncol; 2011 Aug; 122(2):324-7. PubMed ID: 21620446
[TBL] [Abstract] [Full Text] [Related]
17. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma.
Tada H; Teramukai S; Fukushima M; Sasaki H
BMC Cancer; 2009 Feb; 9():47. PubMed ID: 19193243
[TBL] [Abstract] [Full Text] [Related]
18. Iridium-192 transperineal interstitial brachytherapy for locally advanced or recurrent gynecological malignancies.
Gupta AK; Vicini FA; Frazier AJ; Barth-Jones DC; Edmundson GK; Mele E; Gustafson GS; Martinez AA
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1055-60. PubMed ID: 10192355
[TBL] [Abstract] [Full Text] [Related]
